Efficacy and safety of ibrutinib in relapsed/refractory CLL and SLL in Japan: a post-marketing surveillance.

Omi, Ai; Nomura, Fumi; Tsujioka, Shigeharu; Fujino, Akiko; Akizuki, Reiko

Omi, Ai; Nomura, Fumi; Tsujioka, Shigeharu; Fujino, Akiko; Akizuki, Reiko.

Affiliation

Omi A; Medical Affairs Division, Janssen Pharmaceutical K.K., Tokyo, Japan.
Nomura F; Safety and Surveillance Division, Janssen Pharmaceutical K.K., Tokyo, Japan.
Tsujioka S; Safety and Surveillance Division, Janssen Pharmaceutical K.K., Tokyo, Japan.
Fujino A; Safety and Surveillance Division, Janssen Pharmaceutical K.K., Tokyo, Japan.
Akizuki R; Medical Affairs Division, Janssen Pharmaceutical K.K., Tokyo, Japan.

J Clin Exp Hematop ; 62(3): 136-146, 2022 Sep 28.

Article in En | MEDLINE | ID: mdl-35831100

Subject(s)

Leukemia, Lymphocytic, Chronic, B-Cell; Adenine/analogs & derivatives; Humans; Japan/epidemiology; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy; Leukemia, Lymphocytic, Chronic, B-Cell/pathology; Piperidines; Product Surveillance, Postmarketing; Pyrazoles/adverse effects; Pyrimidines/adverse effects; Recurrence

Key words

Chronic lymphocytic leukemia; Japanese patients; ibrutinib; small lymphocytic lymphoma; tyrosine kinase inhibitor

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Lymphocytic, Chronic, B-Cell Type of study: Screening_studies Limits: Humans Country/Region as subject: Asia Language: En Journal: J Clin Exp Hematop Journal subject: HEMATOLOGIA / PATOLOGIA Year: 2022 Type: Article Affiliation country: Japan

Fulltext

XML

PubMed Links

Search on Google